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The RNA-specific adenosine deaminase (ADAR1) is an interferon-inducible editing enzyme that converts adenosine to
inosine. ADAR1 contains three distinct domains: a N-terminal Z-DNA binding domain that includes two Z-DNA binding motifs;
a central double-stranded RNA binding domain that includes three dsRNA binding motifs (dsRBM); and a C-terminal catalytic
domain responsible for A-to-I enzymatic activity. The E3L protein of vaccinia virus mediates interferon resistance. E3L, similar
to ADAR1, also contains Z-DNA binding and dsRNA binding motifs. To assess the possible role of E3L in modulating RNA
editing by ADAR1, we examined the effect of E3L on ADAR1 deaminase activity. Wild-type E3L protein was a potent inhibitor
of ADAR1 deaminase enzymatic activity. Analysis of mutant E3L proteins indicated that the carboxy-proximal dsRBM of E3L
was essential for antagonism of ADAR1. Surprisingly, disruption of the Z-DNA binding domain of E3L by double substitutions
of two highly conserved residues also abolished its antagonistic activity, whereas deletion of the entire Z domain had little
effect on the inhibition. With natural neurotransmitter pre-mRNA substrates, E3L weakly inhibited the site-selective editing
activity by ADAR1 at the R/G site of the glutamate receptor B subunit (GluR-B) pre-mRNA and the A site of serotonin 2C
receptor (5-HT2CR) pre-mRNA; editing of the intronic hotspot (1)60 site of GluR-B was not affected by E3L. These results
demonstrate that the A-to-I RNA editing activity of the IFN-inducible adenosine deaminase is impaired by the product of the
vaccinia virus E3L interferon resistance gene. © 2001 Academic Press
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The interferon (IFN) system is a primary component of
the host innate immune response to viral infection (Biron
and Sen, 2001; Samuel, 2001). Among the IFN-inducible
proteins that mediate the actions of IFN is ADAR1, an
adenosine deaminase that acts on RNA (Patterson and
Samuel, 1995; Samuel, 2001). ADAR1 is a member of the
multigene family of RNA editing enzymes that catalyze
the C-6 deamination of adenosine (A) to yield inosine (I)
in double-stranded (ds) RNA structures (Bass et al.,
1997). A-to-I editing by ADAR is a posttranscriptional
process with the potential to alter mRNA coding and
hence, protein function (Bass, 1997; Keller et al., 1999;
Maas and Rich, 2000). A-to-I conversions can alter splice
site selection in pre-mRNAs (Burns et al., 1997) and can
lead to single amino acid substitutions in mature tran-
scripts (Seeburg et al., 1998; Liu et al., 1999; Liu and
Samuel, 1999), as inosine generated by deamination of
adenosine functions as guanosine.
Two general types of ADAR-catalyzed RNA deamina-
tion are known. First, in some viral RNAs modifications
characteristic of adenosine deamination are found at
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378multiple sites. This is exemplified by the extensive A-to-I
modification seen on viral antisense RNA produced late
in polyoma virus infection (Kumar and Carmichael, 1997)
and by the biased hypermutations found in single-
stranded RNA virus genomes during lytic and persistent
infections (Catteneo, 1994). In the case of measles virus
(MV), these biased hypermutation events are associated
with a change in the pathogenesis of the virus, persistent
infection, and the disease known as subacute sclerosing
panencephalitis (SSPE) (Cattaneo et al., 1988; Wong et
l., 1989; Maas and Rich, 2000). Nonviral examples of
iased hypermutation are also known, as exemplified by
he ion channel transcripts from squid (Patton et al.,
997) and Drosophila (Palladino et al., 2000) and 39-UTR
airpin structures present in poly(A)1 RNA from Caeno-
rhabditis elegans (Morse and Bass, 1999). The second
type of editing process is the highly site-specific A-to-I
deamination limited to one or a few specific adenosines.
Such specific editing is seen in both viral and cellular
RNA substrates, including hepatitis delta virus RNA (Lai,
1995; Polson et al., 1996) and pre-mRNAs in higher ver-
tebrate central nervous systems encoding glutamate re-
ceptor channel subunits and the serotonin 2C receptor
(Seeburg et al., 1998; Liu and Samuel, 1999; Liu et al.,
999; Maas and Rich, 2000).
ADAR1 is an 1226 amino acid protein encoded by an
7-kb mRNA (Patterson and Samuel, 1995; Kim et al.,
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379E3L INTERFERON RESISTANCE PROTEIN INHIBITS ADAR1994; O’Connell et al., 1995). The central region of the
ADAR1 protein contains three functionally distinct copies
of the highly conserved dsRNA binding motif (dsRBM)
that recognizes double-stranded RNA structures (Liu and
Samuel, 1996, Liu et al., 1997). ADAR1 also contains two
-DNA binding domains in the N-terminal region of the
rotein (Herbert et al., 1997; Liu et al., 1998; Kim et al.,
2000). Two forms of human ADAR1 are found in a variety
of cell lines. An IFN-inducible ;150-kDa ADAR1 protein
(p150) is found both in the cytoplasm and in the nucleus
of treated cells, but is absent in untreated cells. A con-
stitutively expressed ;110-kDa truncated protein (p110)
is found predominately if not exclusively in the nucleus of
both untreated and IFN-treated cells (Patterson and
Samuel, 1995). Different promoters, one of which is IFN-
inducible (George and Samuel, 1999a; Patterson et al.,
995), initiate transcription of the ADAR1 gene, and al-
ernative splicing of unique exon 1 structures to a com-
on exon 2 junction generates transcripts with the cod-
ng capacity for either the IFN-inducible p150 or the
onstitutive p110 protein (George and Samuel, 1999b). In
ddition, there are three naturally occurring splice vari-
nts that are differentially expressed in different tissues
Liu et al., 1997, 1999; Liu and Samuel, 1999). These
ariants, which are functionally active, possess altered
pacing between the dsRBM RI and RII motifs and the
-terminal region catalytic domain.
Vaccinia virus encodes several proteins that antago-
ize the actions of interferon (Knipe et al., 2001). These
viral proteins act either by molecular mimicry to disrupt
signaling through the IFN receptor (B8R, B18R) or by
inhibiting the biochemical activity of IFN-induced en-
zymes (E3L, K3L). The E3L gene product allows vaccinia
virus to multiply in cells treated with type I IFNs (Beattie
et al., 1991, 1995; Chang et al., 1995; Davies et al., 1993).
he E3L gene is expressed early during viral infection;
he main gene product is an 190 amino acid (;25-kDa)
rotein. E3L, similar to ADAR1, possesses dsRNA bind-
ng and Z-DNA binding motifs. E3L contains one copy of
he dsRBM that is present in the C-terminal half of the
iral protein (Chang et al., 1992; Chang and Jacobs, 1993;
uwen et al., 1993). The N-terminal half of E3L includes
ne Z-DNA binding motif (Patterson and Samuel, 1995;
erbert et al., 1997). E3L, similar to the p150 form of
DAR, is found in both the cytoplasm and the nucleus,
ith nuclear localization being dependent on the N-
erminal region (Chang et al., 1995; Yuwen et al., 1993).
Vaccinia virus lacking E3L does not replicate effi-
iently in the presence of IFN and has a restricted host
ange (Chang et al., 1995). Resistance to IFN is restored
upon transient transfection of E3L (Chang et al., 1995), by
recombinant E3L introduced into the virus itself (Shors et
al., 1997), or by expression of another dsRNA binding
protein such as the reovirus s3 protein that complements
the loss of E3L (Beattie et al., 1995). Functional dsRNA
binding activity is required for the IFN-resistant pheno-type. Mutations that destroy the ability of E3L to bind
dsRNA destroy the ability of the protein to rescue vac-
cinia virus replication in the presence of IFN. In contrast,
deleting the N-terminal region does not seem to affect
the ability of E3L to rescue viral replication in cell culture
(Chang et al., 1995; Shors et al., 1997). E3L has been
shown to inhibit both the PKR kinase (Watson et al., 1991;
Chang et al., 1992; Jagus and Gray, 1994) and the 29–59
oligoadenylate synthetase (Rivas et al., 1998) by seques-
tering dsRNA. Additional studies indicate that E3L phys-
ically interacts with PKR under some conditions, provid-
ing another possible mechanism for inhibition in addition
to sequestering activator RNA (Romano et al., 1998;
Sharp et al., 1998).
Because of the high degree of domain homology be-
tween the ADAR1 and E3L proteins (Patterson and Sam-
uel, 1995), together with the established role of E3L in
viral pathogenesis and in providing resistance to the
actions of IFN (Brandt and Jacobs, 2001), we examined
the effects of E3L on ADAR1 enzymatic activity. We found
that E3L was a potent inhibitor of ADAR1 deaminase
activity measured on synthetic dsRNA substrates, but
that A-to-I editing of the natural GluR-B and 5HT2C sub-
strates by ADAR1 was inhibited to a much lesser degree.
Both the carboxy- and amino-terminal domains of E3L
played a role in antagonism of ADAR1 activity.
RESULTS
Vaccinia virus E3L protein antagonizes the activity of
the dsRNA-specific adenosine deaminase ADAR1
The 190 amino acid E3L protein and the 1226 amino
acid ADAR1 protein both possess Z-DNA binding and
dsRNA binding domains (Fig. 1). Because of this homol-
ogy, and the role of E3L in pathogenesis, we considered
the possibility that E3L may affect the activity of ADAR1.
To test the effect of E3L on ADAR1 deaminase activity,
we coexpressed E3L and ADAR1 proteins in transfected
COS cells. Adenosine deaminase activity of the recom-
binant His-tagged ADAR1 enzyme was then measured
with a synthetic dsRNA substrate by the TLC assay.
Coexpression of wild-type E3L protein in cells with
ADAR1 efficiently suppressed deaminase activity (Fig. 2;
lanes 7 and 8). Cells transfected with ADAR1 alone (Fig.
2, lane 4) or doubly transfected with ADAR1 and the
empty pMT vector (Fig. 2, lanes 5 and 6), displayed
significant A-to-I editing activity. Endogenous deaminase
activity was detectable, but the level was very low in
cells transfected only with empty vectors lacking either
the E3L (Fig. 2, lane 1) or the ADAR1 (Fig. 2, lane 2) cDNA
insert. Furthermore, the low endogenous activity that
was detectable was reduced even further to a level now
below that necessary for detection by expression of
wild-type E3L alone in singly transfected cells (Fig. 2,
lane 3).
We next examined the effect of varying concentrations
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380 LIU ET AL.of recombinant wild-type E3L protein on deaminase ac-
tivity (Fig. 3). Deamination catalyzed by ADAR1 M296-b
was inhibited by wild-type E3L protein (Fig. 3A) in a
dose-dependent fashion (Fig. 3B). Complete inhibition
was observed when the molar ratio of E3L and ADAR1
proteins was ;3 to 1.
Two splice variants of the full-length p150 form of
ADAR1 (FL) and the N-terminal truncated p110 form
(M296), designated as “a” and “b”, are known to occur in
a variety of cells and tissues (Liu et al., 1997, 1999). Both
he a and b splice variants of ADAR, in the form of
FIG. 1. Functional domains of human ADAR1 deaminase and vac-
cinia virus E3L proteins are shown on schematic structures for wild-
type and mutant cDNA constructs examined in this study. (A) ADAR1
possesses three copies (RI, RII, RIII) of the dsRNA binding motif in the
central dsRNA binding domain (dsRBD) and two Z-DNA binding motifs
(Za, Zb) in the N-terminal Z-DNA binding domain (ZBD) that were
riginally identified as homologous to the E3L protein (Patterson and
amuel, 1995). The catalytic domain (C) is located in the C-terminal
egion. The methionine residues at position 1 and 296 of the ORF were
tilized, respectively, to express the full-length (FL, p150) or the N-
erminally truncated (M296, p110) forms of ADAR1 (Patterson and Sam-
el, 1995; George and Samuel, 1999b); a and b refer to natural splice
ariants of ADAR1 (Liu et al., 1997). The internal deletion mutant of
DAR1 (M1-a-DZab) lacks the two Z-DNA-binding domains (Liu et al.,
000). (B) Vaccinia virus E3L protein possesses one Z-DNA-binding
otif in the N-terminal region and one dsRNA binding motif domain
ear the C-terminus. Different deletion and substitution mutants of E3L
re also indicated.ull-length and M296 proteins, were inhibited by wild-
ype E3L protein (Table 1). The Za and Zb DNA-binding
s
sdomains found in the N-terminal region of FL ADAR1 (Fig.
1A) were not required in order for E3L to mediate the
observed inhibition of deaminase activity. Comparable
antagonism was seen with the M1-a-DZab deletion mu-
tant ADAR1 protein as with the FL and M296 ADAR1
proteins (Table 1). The specific activities of the M1-a-
DZab deletion mutant, FL, and M296 ADAR1 proteins
measured in the absence of added E3L with a synthetic
dsRNA substrate are comparable (data not shown; Liu et
al., 2000). Single amino acid substitution mutants of
ADAR1, possessing mutations that inactivate the RNA-
binding activity of the RI (K554E) or the RII (K665E)
sRBM, are active deaminases with both synthetic (Liu
nd Samuel, 1996) and natural (Liu and Samuel, 1999; Liu
t al., 1999) RNA substrates. These mutations in the RI
and RII motifs did not impair the ability of E3L to antag-
nize deaminase activity (Table 1).
ntact dsRBM domain of E3L is essential for
ntagonism of ADAR1 deaminase
To further define the requirements for antagonism of
DAR1 enzyme activity, different mutant versions of vac-
inia virus E3L as well as the s3 protein of reovirus were
examined. Unlike the wild-type E3L protein (Fig. 4A, lane
2), the reovirus s3 protein, which also is a dsRNA binding
protein (Miller and Samuel, 1992), was incapable of an-
FIG. 2. Antagonism of ADAR1 adenosine deaminase activity by E3L
protein. Extracts from COS cells singly or doubly transfected were
analyzed for deaminase activity. Cells were singly transfected either
with empty expression vectors (lanes 1 and 2), vectors expressing E3L
protein (lane 3), or with His-tagged M296-b form of ADAR1 deaminase
(lane 4). Cotransfections were done with pHis vector expressing
M296-b in the presence of different amounts of either empty pMT2
vector (lanes 5 and 6) or pMT2 vector expressing E3L protein (lanes 7
and 8). A synthetic 32P-labeled dsRNA substrate was used in thetandard thin layer chromatography (TLC) deaminase assay to mea-
ure inosine formation.
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381E3L INTERFERON RESISTANCE PROTEIN INHIBITS ADARtagonizing ADAR1 (Fig. 4A, lane 8). Deletion of either 7 or
26 amino acids from the C-terminal region of E3L (D7C
and D26C) abolished the ability of E3L to inhibit ADAR
(Fig. 4A, lanes 4 and 5). By contrast, deletion of 83 amino
acids from the N-terminal region of E3L (D83N), a trun-
cation that removes the entire Z-DNA binding domain of
E3L, did not significantly reduce antagonistic activity
(Fig. 4A, lane 3). The E3L substitution mutant G164V that
contains a mutation in the dsRBM (Fig. 1B) which dis-
rupts the dsRNA binding activity did not inhibit ADAR1
(Fig. 4A, lane 7), whereas the G164A substitution mutant
that retains dsRNA binding activity (Chang and Jacobs,
1993) inhibited ADAR1 deaminase activity. All of the C-
terminal deletion and substitution mutants of E3L, but not
the N-terminal D83N mutant or reovirus s3, were effi-
ciently detected by anti-E3L polyclonal antiserum (Fig.
4B).
The relative activity of ADAR1 was quantified using
reaction mixtures that contained an amount of E3L mu-
tant protein (Fig. 5) equivalent to the amount of wild-type
FIG. 3. Dose-dependent antagonism of ADAR1 deaminase by E3L
protein. (A) Standard TLC deaminase assays for recombinant M296-b
ADAR1 showing the antagonistic effect of varying amounts of recombinant
E3L protein on antagonism of deaminase activity. (B) Relative deaminase
activities were calculated based on percentage of A-to-I conversion by
M296-b in the presence of increasing amounts of E3L protein. Error bars
were determined from two or three independent experiments.E3L protein that gave ;90% inhibition of deaminase
ctivity (Fig. 3B). Wild-type E3L was the most potent E3L
Gntagonist of ADAR1. Deletion mutant D83N completely
acking the Z binding domain and the single substitution
utant G164A in dsRBM both retained significant inhib-
tory activity. However disruption of the dsRBM function,
ither by truncation as with D7C or D26C or substitution
as with G164V, dramatically reduced the antagonistic
activity of E3L. Surprisingly, in contrast to the deletion of
the entire Z-DNA binding domain as with D83N, the
double substitution mutant N44A/W66L within the Z-DNA
binding domain (Fig. 1B) completely abolished the inhib-
itory activity of E3L (Fig. 5). The s3 protein of reovirus did
not significantly alter ADAR1 activity (Figs. 4 and 5).
Lack of correlation of E3L dsRNA binding activity with
antagonism of ADAR1
Two mutants of E3L, the N44A/W66L double substitu-
tion mutant and the D7C deletion mutant, both possess
an intact wild-type sequence in the region including the
dsRBM motif (Fig. 1B). However, these mutants did not
antagonize deaminase activity when tested at a concen-
tration similar to wild-type E3L protein that effectively
TABLE 1
E3L-Mediated Antagonism of dsRNA-Specific Deamination
Catalyzed by Different Wild-Type and Mutant ADAR1 Proteins
ADAR1
E3L(WT)
2
%
1
%
FL-a [100 12.1
FL-b [100 9.1 6 3.8
M296-a [100 13.9 6 0.6
M296-b [100 7.0 6 5.1
M1-a-DZab [100 13.7
M296-b-RI [100 6.5 6 0.7
M296-b-RII [100 5.2 6 3.1
Note. The relative deaminase activity for each recombinant ADAR1
enzyme was measured with a synthetic dsRNA substrate. Activity
measured in the presence of wild-type E3L was normalized to that
measured in the absence of E3L, set at 100%.
TABLE 2
Ability of Wild-Type and Mutant E3L Proteins to Bind and
Antagonize dsRNA Deamination Catalyzed by ADAR1
E3L dsRNA binding activity ADAR inhibition
T 1 1
44A 1 2
66L
83N ND 1
7C 1 2
26C 2 2
164A 1 1
164V 2 2
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382 LIU ET AL.abolished ADAR1 deaminase activity (Figs. 2 and 5). To
further assess the possible requirement of dsRNA-bind-
ing activity of E3L for the inhibition of ADAR1 deaminase
enzymatic activity, we next measured the ability of wild-
type and mutant forms of E3L and ADAR1 proteins to
bind the identical synthetic dsRNA that was used as the
substrate in the enzymatic analyses. The amount of 32P-
labeled dsRNA substrate bound either by ADAR1 or by
E3L following immunoprecipitation with antiepitope
monoclonal antibody (Figs. 6A and 6C) or polyclonal
antiserum (Figs. 6B and 6D) was quantified. When His-
tagged wild-type ADAR1 was precipitated using either
anti-X epitope tag monoclonal antibody (Fig. 6A) or poly-
clonal antiserum raised against recombinant ADAR1 pro-
tein (Fig. 6B), bound dsRNA was efficiently coprecipi-
tated with the ADAR1 wild-type protein but not the triple
R mutant (RIRIIRIII) protein in which all three dsRBMs are
disrupted by substitution mutations (Figs. 6A and 6B).
FIG. 4. Antagonism of ADAR1 deaminase activity by wild-type and
mutant versions of recombinant vaccinia virus E3L but not reovirus s3
proteins. (A) Standard TLC deamination assay to measure inosine
formation catalyzed by M296-b ADAR1 in the presence of cytoplasmic
extract from COS cells transfected with either empty vector (lane 1) or
vectors expressing wild-type or mutant forms of E3L (lanes 2–7) or the
wild-type s3 protein of reovirus encoded by the S4 gene (lane 8). (B)
estern immunoblot analysis of expressed wild-type and mutant E3L
roteins (lanes 2–7) using polyclonal antibody against vaccinia E3L
lanes 1–8A) or reovirion capsid proteins (lane 8B).When His-tagged E3L proteins synthesized either in vitro
in reticulocyte lysates (Fig. 6C) or expressed in trans-fected COS cells (Fig. 6D) were analyzed, both wild-type
E3L and the N44A/W66L mutant E3L protein efficiently
bound dsRNA. Consistent with earlier reports (ref), nei-
ther the G164V single substitution mutant (Fig. 6C) nor
the 26C deletion mutant (Fig. 6D) bound significant
amounts of dsRNA under similar conditions. However
the D7C mutant lacking the C-terminal seven amino acid
residues, but still retaining an intact dsRBM sequence,
possessed comparable dsRNA binding activity to that of
wild-type E3L protein (Fig. 6D). These results, taken to-
gether, indicate that the dsRNA binding activity of E3L
per se is not sufficient for antagonism of ADAR1 deami-
nase activity.
Ability of E3L to antagonize the site-selective editing
of GluR-B and 5-HT2C R pre-mRNAs
We next examined the ability of E3L recombinant pro-
teins to inhibit site-selective editing in vitro by ADAR1 of
the two known natural RNA substrates, the glutamate
receptor GluR-B exon 13 R/G site and the serotonin 2c
receptor exon 3 A site (Burns et al., 1997; Seeburg et al.,
1998). For the R/G site of the GluR-B substrate, A-to-I
editing catalyzed by ADAR1 was reduced only ;50% by
either the wild-type E3L or the DN83 mutant protein,
whereas neither the D7C E3L mutant or the wild-type s3
protein significantly reduced editing (Fig. 7A). Similar
inhibitory results were observed when the A site of the
5-HT2CR RNA substrate was analyzed (Fig. 7B). No inhi-
ition of A-to-I editing was observed for the intronic
otspot (1)60 site of GluR-B RNA (data not shown).
DISCUSSION
The results reported herein establish that the vaccinia
irus E3L gene product impairs the enzymatic activity of
DAR, an IFN-inducible RNA-specific adenosine deami-
FIG. 5. Quantitation of ADAR1 deaminase activity measured in the
absence or presence of either vaccinia virus E3L or reovirus s3 pro-
teins. A synthetic 32P-labeled dsRNA substrate was used in the stan-
dard adenosine deaminase assay for M296-b ADAR1. Deamination
efficiencies in the presence of E3L proteins as well as the s3 protein
were calculated and normalized to that using empty vector. Error bars
were determined from two to three independent experiments.
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383E3L INTERFERON RESISTANCE PROTEIN INHIBITS ADARnase that catalyzes C-6 deamination of adenosine to
yield inosine. This finding has broad implications related
to the possible role of A-to-I editing in the actions of IFN
and the pathogenesis of poxviruses.
Vaccinia virus E3L is an early gene product with an
established role in virus resistance to IFN and pathogen-
esis in the mouse model (Brandt and Jacobs, 2001; Shors
et al., 1997, 1998). Our results show that E3L can inhibit
ADAR1 deaminase activity. Both natural ADAR1 present
in extracts prepared from cultured cells and recombinant
ADAR1 expressed in transfected COS cells were inhib-
ited by E3L. The inhibition of deaminase activity by E3L
was observed with recombinant ADAR enzyme (FL-a)
that possesses both copies of the Z-DNA binding motif
(Za, Zb) and with truncated ADAR enzymes that lack only
Za (M296-a) or both Za and Zb (M1-a-DZaZb). The N-
erminal region of the 1226 amino acid ADAR protein is
ispensable for A-to-I editing activity of synthetic dsRNA
nd the natural pre-mRNA substrates for GluR-B and
FIG. 6. dsRNA binding activities of mutant E3L and ADAR1 proteins. S
activities of recombinant ADAR1 and E3L proteins. The wild-type an
monoclonal antibody against the Xpress epitope or (B) polyclonal ant
1995). Wild-type and mutant E3L proteins synthesized either as His-tag
(D) were likewise analyzed for binding activity using monoclonal and-HT-2c receptors as shown herein and reported else-
here (Liu and Samuel, 1999; Liu et al., 1999, 2000). This
H
aegion of ADAR1, including the N-terminal residues 1 to
355, also was not required for antagonism by E3L.
nactivation of either the RI(K554E) or the RII(K665E) RNA-
inding motif of ADAR by mutation did not abolish an-
agonism of deaminase activity by E3L. Because the
ingle amino acid substitution that inactivates binding at
he RIII(K776E) motif of ADAR effectively abolishes deami-
ase activity (Liu and Samuel, 1996; Liu et al., 1997), this
utant could not be tested for antagonism. E3L pos-
esses a single dsRBM motif within the C-terminal re-
ion, and this domain was essential for the ability of E3L
o antagonize ADAR deaminase activity.
The principle functions previously elucidated for the
3L protein relate to its ability to antagonize the activa-
ion of two enzymes: PKR, the RNA-dependent kinase
hat modulates the activity of translation factor eIF-2
Samuel, 1979; Chang et al., 1992); and OAS, the RNA-
ependent oligoadenylate synthetase that produces the
9,59-oligoadenylate activator of RNase L (Rebouillat and
ic 32P-labeled dsRNA substrate was used to assess the dsRNA binding
R mutant forms of M296-b ADAR1 were analyzed using either (A)
repared against recombinant ADAR1 protein (Patterson and Samuel,
oteins by in vitro translation (C) or expressed in transfected COS cells
nal antibodies, respectively.ynthet
d triple
ibody povanessian, 1999; Rivas et al., 1998). Both PKR and OAS
re IFN-inducible proteins that play key roles in the
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384 LIU ET AL.antiviral and antiproliferative actions of IFNs (Samuel,
2001). It is well established that vaccinia virus is rela-
tively resistant to the antiviral actions of IFN (Youngner et
al., 1972; Shors et al., 1998). This resistance is due, at
east in part, to the antagonism by E3L of PKR and OAS
unctions, thereby restoring the translational system and
resumably facilitating virus replication in infected cells.
he inhibition of PKR and OAS by E3L is dependent upon
he ability of E3L to bind and sequester dsRNA (Chang et
l., 1995). Although in yeast a physical interaction can be
emonstrated between E3L and PKR (Romano et al.,
998; Sharp et al., 1998), such a complex formation has
ot been described between E3L and OAS (Rivas et al.,
998, Rebouillat and Hovanessian, 1999). In the case of
KR, both the C-terminal end of the PKR protein lacking
sRBM and the N-terminal regulatory region containing
he dsRBM interact with E3L (Sharp et al., 1998); complex
ormation requires functional dsRNA binding activity of
3L and is enhanced by the presence of the N-terminal
egion of E3L (Romano et al., 1998). We so far have not
een able to demonstrate a physical interaction between
3L and ADAR1 by in vitro pull-down assays using
DAR1 linked to solid-support matrices or by coimmu-
oprecipitation assays (K. C. Wolff, Y. Liu, and C. E.
amuel, unpublished observations).
Heterologous RNA-binding proteins including the reo-
irus s3 protein can functionally complement vaccinia
irus mutants lacking E3L in mammalian cell culture
Beattie et al., 1995). However, the reovirus s3 protein did
ot antagonize ADAR1 activity in a manner seen with
3L, suggesting that the mode of action of these proteins
ay not be entirely overlapping. Indeed, different poxvi-
us genes appear primarily responsible for the rescue of
ifferent IFN-sensitive viruses from the antiviral actions
f IFN in cultured cells, with E3L important for the rescue
FIG. 7. Effect of E3L on the site-selective editing of glutamate GluR-B
and serotonin 5-HT2CR receptor pre-mRNAs in vitro. Quantitation of the
A-to-I editing catalyzed by M296-b ADAR1 was done in the presence of
wild-type and mutant vaccinia virus E3L proteins, as well as the reo-
virus s3 protein, for the GluR-B R/G site and 5-HT2CR A site. Editing by
elective adenosine deamination was measured using poisoned
rimer extension assays (Liu and Samuel, 1999; Liu et al., 1999). Error
ars were from two independent experiments.f vesicular stomatitis virus and K3L for the rescue of
ncephalomyocarditis virus (Shors et al., 1998). The ob-
a
Servation that E3L protein did not significantly antago-
ize A-to-I editing at the R/G site of the GluR-B RNA or
he A-site of 5HT-2C-R RNA, but did antagonize editing of
sRNA, suggests that one mode of E3L function is the
inding and possible sequestering of substrate RNA.
owever, indications of a second mode of action emerge
rom our results. Two mutants, the N44AW66L substitu-
ion mutant and the D7C deletion mutant, both retained
heir ability to bind dsRNA; nevertheless they did not
ignificantly antagonize ADAR1 activity. The deletion mu-
ant D83N that lacks the Z-DNA binding domain of E3L
ffectively antagonized ADAR1 editing activity even
hough the N44AW66L substitution mutant did not. The
ifferent behavior displayed by the D83N and N44AW66L
utants suggests that protein conformation, likely dic-
ated in part by the N-terminal region of the E3L protein
hat contains the Z-domain, affects biochemical function
f the E3L in a manner that is mediated by the C-terminal
egion that includes the dsRBM motif. Although duplexes
f A-dsRNA and B-dsDNA are structurally very different,
hey adopt similar left-handed Z-conformations. Interest-
ngly, the Z-domain has been shown to bind Z-RNA as
ell as Z-DNA (Brown et al., 2000, Liu et al., 1998).
ence, binding of either RNA or DNA by the Z-domain
as the potential to induce conformational changes that
ffect protein function by altering subsequent protein–
rotein interactions, protein–dsRNA interactions involv-
ng the C-terminal region dsRBM motif, or both.
The physiological relevance of antagonism by E3L of
he A-to-I editing activity of ADAR1 is potentially very
road, as editing patterns and hence function of viral and
ellular transcripts could be changed. Antagonism of the
FN-inducible ADAR1 by vaccinia E3L might contribute to
he antagonism of the antiviral action of IFN seen with
oxviruses (Samuel, 2001). One mechanism might in-
olve RNA degradation of I-containing RNA transcripts.
or example, a ribonuclease specific for inosine-contain-
ng RNA has been identified in HeLa cells (Scadden and
mith, 1997). The IFN-inducible ADAR1 deaminase might
onceivably work in concert with the RNase specific for
nosine-containing RNAs, analogous to the manner in
hich the IFN-inducible 29,59-oligoadenylate synthetase
unctions to produce 29,59-oligoadenylate activators of
he constitutive RNase L (Biron and Sen, 2001; Samuel,
001).
Changing genetic information through RNA editing
rovides a mechanism by which functionally distinct pro-
eins can be produced that subsequently modulate im-
ortant physiological responses (Maas and Rich, 2000).
his is illustrated most convincingly by the examples of
elective A-to-I editing of pre-mRNA transcripts encoding
ellular receptors for two neurotransmitters, glutamate
nd serotonin, that lead to specific amino acid substitu-
ions that profoundly affect receptor function (Seeburg et
l., 1998; Burns et al., 1997; Liu et al., 1999; Liu and
amuel, 1999). A-to-I editing can also alter the splicing
fd
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385E3L INTERFERON RESISTANCE PROTEIN INHIBITS ADARpattern of pre-mRNA transcripts, for example, by creation
of an alternative splice-acceptor site that subsequently
leads to the generation of a mature transcript with al-
tered coding potential (Rueter et al., 1999). Inosine is
ound in poly(A)1 RNA from many tissues, but is most
abundant in brain mRNAs (Paul and Bass, 1998). An
intriguing possibility that now must be considered is that
poxvirus infection leads to an alteration in the editing of
cellular RNA transcripts, including neuron-specific RNAs
in a manner that alters the virus–host interaction. Vac-
cinia virus lacking E3L is apathogenic after intracranial
infection, whereas wild-type vaccinia virus is highly neu-
rovirulent in the mouse model when animals are infected
intracranially (Brandt and Jacobs, 2001). Vaccinia virus
expressing E3L lacking the N-terminus (E3LD83N) is IFN
resistant and displays broad host range and good via-
bility in cell culture (Chang et al., 1995; Shors et al., 1998;
Brandt and Jacobs, 2001). Interestingly, in the mouse
model, virus carrying the D83N deletion is much less
virulent than virus with wild-type E3L (Brandt and Jacobs,
2001), suggesting that the N-terminal region of the E3L
protein fulfills a significant function within the animal
host that affects pathogenesis independent of the role in
antagonizing the antiviral response of IFN as measured
by virus replication studies (Shors et al., 1998; Brandt and
Jacobs, 2001).
MATERIALS AND METHODS
Construction of plasmid expression vectors
All N-terminally His-tagged ADAR1 eukaryotic expres-
sion vectors were constructed in pcDNA3.1/HisC (Invitro-
gen), denoted herein as pHis constructs. The N-termi-
nally truncated (p110) forms of ADAR1 starting from the
second methionine of the ADAR1 ORF located at position
296 (M296), including the two splice site variants
ADAR1-a and -b (Fig. 1A), were constructed by subclon-
ing the BamHI–XhoI fragment of the ADAR1 cDNA
(Patterson and Samuel, 1995) from the corresponding
pcDNA I/Neo plasmids (Liu and Samuel, 1996; Liu et al.,
1997, 2000). The full-length forms (p150) starting from the
first methionine of the ORF (Fig. 1A) were obtained by
subcloning the N-terminal BamHI–BamHI fragment of the
ADAR1 cDNA into the BamHI site of pHis-M296-ADAR1
expression vector constructs. The ADAR1 deletion mu-
tant M1-a-DZab, which lacks the two Z domains, was
erived from the ADAR1 deletion mutant DL2 construct
Liu and Samuel, 1996; Liu et al., 2000). The ADAR1
ubstitution mutants in the dsRNA binding motifs (JV,
BC), the single R mutants RI(K554E) and RII (K665E), and
the triple R mutant RIRIIRIII (K554E, K665E, K776E), were
likewise constructed in pHis vectors.
All E3L expression vectors were in the pMT2 plasmid
(Chang and Jacobs, 1993; Shors et al., 1997). These include
he wild-type (WT) E3L construct and the following E3L
utant constructs: D83N, a N-terminally truncated form of3L with 83 amino acid residues deleted; D7C and D26C,
-terminally truncated versions of E3L with either 7 (D7C) or
6 (D26C) residues deleted; and G164A and G164V, two
ingle substitution mutants in the dsRBM. The E3L double-
ubstitution mutant (N44A, W66L) in the Z-DNA binding
otif was derived from the pMP E3L-NW plasmid by sub-
loning into pMT2 vector the PstI–EcoRI fragment of PCR
roduct amplified using primers 59-GCCTGCAGGCCAT-
TCTAAGATCTATATTGACG-39 and 59-GCGAATTCTCAGA-
TCTAATGATGACGTAACCAAG-39. The N-terminally His-
agged E3L expression vectors, which included WT, NW,
nd G164V, were constructed by subcloning the PstI–EcoRI
ragments of E3L cDNA from pMT2 vectors with the PstI
ite blunted using T4 DNA polymerase into the pcDNA3.1/
isC vector that had been digested with BamHI–EcoRI with
he BamHI site blunted similarly. The reovirus s3 protein
expression vector, pSV-S4, was as previously described
(Munemitsu and Samuel, 1988).
Expression of the recombinant ADAR1 and E3L
proteins
All recombinant His-tagged ADAR1 and E3L proteins
(Fig. 1), as well as s3 protein of reovirus, were expressed
in transfected monkey kidney COS-1 cells using the
DEAE–dextran–chloroquine phosphate method (Luth-
man and Magnusson, 1983; Munemitsu and Samuel,
1988). Cotransfections were carried out using pHis-
ADAR1 and indicated amounts of pMT2-E3L DNA. Cyto-
plasmic fractions of COS cell extracts, which are free of
the endogenous nuclear ADAR enzymes (Patterson and
Samuel, 1995, Liu et al., 1997), were prepared by NP-40
lysis and used as the source of expressed recombinant
proteins as previously described in detail (Liu et al., 1997,
1998). His-tagged E3L proteins were synthesized using
the rabbit reticulocyte lysate system (Promega) and in
vitro transcribed E3L mRNA according to the manufac-
turer’s instructions. Western immunoblot analysis was
carried out to quantitate protein levels using either the
monoclonal antibody against the anti-Xpress epitope fol-
lowing the His tag or the polyclonal antisera generated
against recombinant ADAR1 protein expressed in Esch-
erichia coli (Patterson and Samuel, 1995) or E3L protein
(Watson et al., 1991). Antibody–antigen complexes were
subsequently detected with ECL Western blotting analy-
sis system (Amersham Pharmacia Biotech) followed by
quantitation with the molecular imager (Bio-Rad GS-525).
Analysis of antagonism of A-to-I RNA editing activity
in vitro
Two types of assays were used to measure RNA-
specific adenosine deamination catalyzed by ADAR1.
RNA deamination of a 32P-labeled fully complementary
synthetic dsRNA substrate was measured by a thin-layer
chromatography (TLC)-based assay (Patterson and Sam-
uel, 1995; Liu and Samuel, 1996). Primer extension-based
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were used to measure site-selective editing activity (Liu
and Samuel, 1999; Liu et al., 1999). To test for antago-
ism, recombinant E3L or s3 proteins were added to the
ADAR1 reaction mixture. For a standard 40-ml deamina-
tion assay, 20 ml ADAR1 cytoplasmic extract was incu-
ated with dsRNA substrate in the presence of 10 ml
wild-type E3L extract for 2 h at 30°C. Comparable
amounts of the different mutant E3L proteins were ex-
amined based upon Western blotting analysis. Extract
prepared from cells transfected with empty vector were
used as a control to maintain constant extract volumes in
the reaction mixtures. Inosine formation resulting from
the deamination of adenosine using a synthetic dsRNA
substrate was analyzed by TLC following hydrolysis of
the deaminated dsRNA product with nuclease P1 (Phar-
macia). With the natural GluR-B pre-mRNA substrate,
measurements of editing efficiency at the intronic hot-
spot (1)60 and the exon 13 R/G sites were done using
RT-based poisoned primer extension assays (Liu and
Samuel, 1999); for the 5-HT2CR substrate RNA, a poi-
oned primer extension strategy was also employed to
etermine the editing efficiency at the A and C sites (Liu
t al., 1999). Extended products were resolved on dena-
uring 16% PAGE gel with 7 M urea. All quantitations were
one using a Bio-Rad GS-525 molecular imager system.
rror bars shown in the figures were determined from
wo to three independent experiments.
oimmunoprecipitation-coupled dsRNA binding
ssays
The 32P-labeled synthetic dsRNA substrate was incu-
ated with recombinant ADAR1 or E3L proteins on ice for
0 min in NP-40 lysis buffer. Indicated antibodies were
hen added, and incubation was continued on ice. The
ound dsRNA was subsequently recovered using CL-4B
rotein A Sepharose beads (Pharmacia); beads were
ashed twice extensively with lysis buffer before mea-
urement of 32P using a Beckman LS1801 liquid scintil-
ation system.
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